
-
Turkey's opposition says Erdogan's canal plan behind latest arrests
-
Maresca hails 'nasty' Chelsea as top five bid stays alive
-
Trump raises Putin doubts after Zelensky talks at pope's funeral
-
Major blast at Iran port kills 4, injures hundreds
-
Napoleon's sword to be sold at auction in Paris
-
Iran, US discuss nuclear deal in third round of talks
-
Buenos Aires farewells native pontiff with call to action
-
Warholm sets hurdles world record at Diamond League, Holloway shocked
-
US students 'race' sperm in reproductive health stunt
-
Wikileaks founder Assange joins crowds for pope funeral
-
Leader Marc Marquez claims Spanish MotoGP sprint victory
-
Celtic win fourth successive Scottish Premiership title
-
Jackson ends drought as Chelsea boost top five push
-
Warholm sets 300m hurdles world record in Diamond League opener
-
Major blast at south Iran port kills 4, injures hundreds
-
Russia says retook Kursk from Ukraine with North Korean help
-
Francis laid to rest as 400,000 mourn pope 'with an open heart'
-
Trump, Zelensky meet on sidelines of pope's funeral
-
'Shared loss': Filipino Catholics bid Pope Francis farewell
-
Families unable to reunite as India-Pakistan border slams shut
-
Major blast at south Iran port injures hundreds
-
Foreign carmakers strive for 'China Speed' to stay in race
-
Pakistan says open to neutral probe into Kashmir attack after India threats
-
Hundreds of thousands at funeral mourn pope 'with an open heart'
-
Quartararo sets Spanish MotoGP record to claim pole
-
Hamas says open to 5-year Gaza truce, one-time hostages release
-
Iran, US hold new round of high-stakes nuclear talks
-
Up at dawn for front-row seat to history at Francis's funeral
-
Pakistan ready to 'defend sovereignty' after India threats
-
Huge crowds flock to Vatican for Pope Francis's funeral
-
Xi says China must 'overcome' AI chip challenges
-
Indian army says new exchange of gunfire with Pakistan
-
Epstein accuser Virginia Giuffre takes own life in Australia: family
-
Hundreds of buildings damaged, dozens injured in 6.3 Ecuador quake
-
India and Pakistan's Kashmir fallout hits economy too
-
Francis's funeral to be grand farewell to 'pope of the poor'
-
Pogacar faces defiant Evenepoel at Liege-Bastogne-Liege
-
Chelsea eye great escape against Barcelona in Women's Champions League
-
Iran, US to hold new round of high-level nuclear talks
-
'Energy and effort' pay off for Reds as Blues' woes continue
-
Albatross and closing birdie lift China's Liu to LPGA Chevron lead
-
On the horizon? Wave of momentum for high seas treaty
-
New to The Street Launches For The Causes(TM) Monthly Awareness Segments: Offering Free National Media to Charities and Organizations
-
Top Mistakes to Avoid When Building Credit History
-
Developing countries should fast-track US trade deals: World Bank president
-
Grizzlies' Morant 'doubtful' for must-win game 4 v Thunder
-
Trump in Rome for pope funeral in first foreign trip of new term
-
Trump says Russia-Ukraine deal 'very close' after new Kremlin talks
-
US rookies lead PGA pairs event with McIlroy and Lowry in hunt
-
Trump tariff promises get a reality check

US makes new Alzheimer's drug more widely accessible
The US drug regulator gave full approval to a new Alzheimer's medicine on Thursday, a move that makes it more widely available to the public through government-run health insurance for the elderly.
Leqembi, developed jointly by Japan's Eisai and Biogen of the United States, was shown in a clinical trial to modestly reduce cognitive decline among patients in the early stages of the disease.
But the study also raised concerns about side effects including brain bleeds and swelling.
Leqembi was initially granted "accelerated approval" by the Food and Drug Administration in January, which meant it was not broadly covered by the government-run Medicare program for people aged 65 and older.
Thursday's decision, which follows further study of the drug, means Medicare will now defray a large portion of treatment, initially listed by the makers at $26,500 per year.
"This confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer's disease," senior FDA official Teresa Buracchio said in a statement.
Chiquita Brooks-LaSure, administrator of the agency that runs Medicare, added: "This is welcome news for the millions of people in this country and their families who are affected by this debilitating disease."
But people covered by Medicare will still need to meet 20 percent of the cost, or thousands of dollars, themselves.
Approximately 6.5 million Americans suffer from Alzheimer's, which is characterized by memory loss and declining mental acuity.
Leqembi, also known as lecanemab, is an antibody treatment that is injected into the brain every two weeks and works by reducing amyloid beta, a protein that builds into plaques and causes brain cells to die, as well as brain shrinkage.
The FDA's decision was welcomed by patient groups.
"This treatment, while not a cure, can give people in the early stages of Alzheimer's more time to maintain their independence and do the things they love," said Joanne Pike, Alzheimer's Association president and CEO.
"This gives people more months of recognizing their spouse, children and grandchildren."
Leqembi was the second Alzheimer's drug developed by Eisai and Biogen to receive approval. The first, Aduhelm, was approved in 2021 but the decision was highly controversial as the data about its efficacy was inconsistent.
In May, US drugmaker Eli Lilly announced its drug donanemab also significantly slowed cognitive decline associated with Alzheimer's, and would soon seek worldwide regulatory approval.
Alzheimer's disease accounts for 60 to 80 percent of dementia, according to the Alzheimer's Association. It progressively destroys thinking and memory, eventually robbing people of the ability to carry out the simplest of tasks.
D.Kaufman--AMWN